Science & Enterprise subscription

Follow us on Twitter

  • A drug targeting immune system enzymes used as a skin cream is shown in a clinical trial to reverse effects of viti… https://t.co/igOhmze2sl
    about 37 mins ago
  • New post on Science and Enterprise: Topical Immune Drug Reverses Skin Disease https://t.co/WzGc3YOFql #Science #Business
    about 43 mins ago
  • Medical researchers and data scientists are using artificial intelligence, or A.I., to diagnose children’s intestin… https://t.co/urHvB81IUx
    about 21 hours ago
  • New post on Science and Enterprise: A.I. Harnessed to Diagnose Children’s Gut Diseases https://t.co/K5JZp5FW7t #Science #Business
    about 21 hours ago
  • University engineers and chemists are creating a more efficient material for separating carbon dioxide from emissio… https://t.co/7hT7j4A6kd
    about 1 day ago

Please share Science & Enterprise

Biotech Lands $5 Million Investment Deal

Israeli Shekels (Michael Plumb/Flickr)Compugen Ltd., a biotechnology company in Tel Aviv, Israel, said today that it will receive $5 million in R&D funding from Baize Investments Ltd., a private Israeli corporation that invests in medical technologies. Compugen is a drug and diagnostic discovery company that bases its work on automated (in silico) analyses and models, including computational biologic tools.

Under the agreement, Baize Investments will receive a financial interest in five Compugen-discovered molecules and has been issued a warrant to purchase 500,000 Compugen shares at an exercise price of $6.00 per share, expiring June 30, 2013. That interest includes the right to receive from Compugen up to 10 percent of certain future payments received by Compugen from third parties in the event of successful licensing out for development or commercialization of those molecules.

All five molecules are now in active research in the Compugen’s pipeline program. That program focuses on oncology and immunology therapeutics, primarily in the form of protein, peptide, and monoclonal antibody drug candidates.

The company started the program earlier this year to expand the number of in silico predicted and selected therapeutic candidates undergoing in vitro and in vivo validation, and to significantly enhance the commercial value of Compugen’s product candidates. In October, compugen added some 20 new molecules to its pipeline, and expects to advance certain candidates by 12 to 18 months beyond the successful animal disease model proof-of-concept stage.

Photo: Michael Plumb/Flickr

*     *     *

Please share Science & Enterprise ...
error

Comments are closed.